Viewing Study NCT03528694


Ignite Creation Date: 2025-12-25 @ 2:00 AM
Ignite Modification Date: 2025-12-26 @ 1:11 AM
Study NCT ID: NCT03528694
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-25
First Post: 2018-02-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module